
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical solution containing benzocaine, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing benzocaine is listed. Products containing it are filed in the directory as over-the-counter monograph drugs and unapproved drugs, in solution, gel, cream, liquid and spray forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Benzocaine is an ester-type local anesthetic that numbs skin and mucous membranes; compounding pharmacies prepare it in topical creams, gels, mouth rinses and suppositories.
Benzocaine is an ester-class local anesthetic. It crosses nerve membranes in its non-ionized form and reversibly blocks voltage-gated sodium channels, which stops nerve fibers from firing pain signals; its very low pKa gives it a fast onset that is largely independent of tissue pH. Single-ingredient manufactured benzocaine is sold over the counter; a prescription-only combination with butamben and tetracaine (Cetacaine) is also marketed, as an unapproved drug. Hurricaine topical anesthetic gel (Beutlich) is labeled for temporary relief of minor irritation and pain from canker sores, sore mouth and throat, minor mouth and gum injury, minor dental procedures and denture or orthodontic irritation, in people 2 years and older. A prescriber may order benzocaine compounded in a strength or vehicle that is not manufactured, in combination with other local anesthetics, or as a suppository or rinse. Compounded preparations are not FDA-approved and require a prescription.
Benzocaine products carry no boxed warning, but FDA asked manufacturers to place a methemoglobinemia warning first under the Warnings heading of every OTC oral benzocaine label: the drug can cause methemoglobinemia, a serious condition that reduces the oxygen carried in blood, even in people who have used it before. Stop use and seek immediate care for pale, gray or blue skin, headache, rapid heart rate, shortness of breath or fatigue. In a 2018 letter FDA cited 119 cases and four deaths from 2009 to 2017, told companies to stop selling benzocaine teething products, and said benzocaine should not be used in children under 2 under any circumstances. Do not use benzocaine if you are allergic to other "caine" anesthetics or to PABA. Dapsone and nitrates raise methemoglobinemia risk; prior methemoglobinemia, G6PD deficiency and heart or lung disease call for caution. Benzocaine has not been studied in breastfeeding; LactMed says it is unlikely to affect the infant if applied away from the breast, but it should not be applied to the breast or nipple, where an infant could swallow it. If side effects are severe or do not go away, talk to your prescriber or pharmacist.
Benzocaine is a PABA ester with pKa about 2.6, so it exists almost entirely non-ionized at tissue pH, diffuses readily into nerve membranes and blocks sodium channels; onset is about 30 seconds at the OTC strength with full effect at 2 to 3 minutes. It is hydrolyzed rapidly by plasma pseudocholinesterase to para-aminobenzoic acid and excreted mainly in urine, with a minor fecal route. Labeled (OTC monograph) uses: temporary relief of minor mouth, gum and throat pain and minor dental procedures in patients 2 years and older (Hurricaine). Prescribers have ordered benzocaine off-label for pharyngitis pain, awake intubation and transesophageal echocardiography topicalization, and to reduce glans sensitivity in premature ejaculation (StatPearls). Dosing, strength and vehicle are per prescriber. Monitoring where systemic exposure is possible: pulse oximetry, which can read falsely normal in methemoglobinemia, ECG and blood pressure; methemoglobin levels above 10 percent cause cyanosis, 15 to 35 percent cause headache, tachycardia and dyspnea, and higher levels cause CNS depression. Treatment is oxygen and intravenous methylene blue; StatPearls notes the risk of methemoglobinemia rises about 20-fold with benzocaine exposure in the prior week. Pregnancy: the older Category C designation, with no studies demonstrating safety. Not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin using the applicator provided or a cotton swab. Let it dry before covering. Use an accurate measuring device if your label gives a volume. Keep it away from the eyes and avoid open flame if the solution contains alcohol. Wash your hands afterward.
Topical solutions are aqueous or alcohol based. Under USP <795>, a preserved aqueous solution usually carries a beyond-use date of up to 35 days; an unpreserved one 14 days refrigerated; a nonaqueous solution may carry up to 180 days. Keep the bottle tightly closed at room temperature, away from heat and flame, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)